Literature DB >> 35692466

The level of interleukin-17, 23, and gamma interferon in cutaneous leishmaniasis patients before and after intra lesion treatment.

Mehdi Ghazanfari1, Bahador Shahriari1,2, Vahid Rahnama1, Meisam Khazaei1, Shahrbanou Naderi1, Mohammad Hossein Motazedian1.   

Abstract

Leishmaniasis is a zoonotic vector-borne disease that is endemic in tropical and sub-tropical districts. The immune system response is one of the most important factors that has affected parasitic treatment. In this research, the production of IL-17 (Interleukin 17), IL-23 (Interleukin 23), and IFN-ɤ (Interferon-gamma) in peripheral blood mononuclear cells (PBMCs) isolated from patients with cutaneous leishmaniasis caused by L. major before and after treatment were compared to evaluate their roles in the recovery process. For this experimental study, we recruited 23 patients in Iran. Ten milliliters of peripheral blood samples were collected before and after one month of treatment, and PBMCs were isolated. Production of IL-17, IL-23, and IFN-ɤ was assessed by sandwich ELISA technique. The production of IFN-ɤ and IL-17 in patients (before treatment sensitive leishmaniasis and resistance leishmaniasis) was more than the healthy controls (P < 0.05). Moreover, both of the cytokines productions in sensitive leishmaniasis cases were more than the resistance leishmaniasis patients. In this study, we observed lower levels of IL-23 in patients compared to healthy controls. And among the patients, IL-23 production was lower in sensitive leishmaniasis cases (P < 0.05).
Conclusion: It appears that the production of IFN-ɤ is necessary for the treatment of leishmaniasis, but further studies are required to address the role of IL-17 and IL-23 in this disease. © Indian Society for Parasitology 2022.

Entities:  

Keywords:  Cutaneous leishmaniasis; IFN ɤ; IL-17; IL-23; PBMC

Year:  2022        PMID: 35692466      PMCID: PMC9177927          DOI: 10.1007/s12639-021-01428-4

Source DB:  PubMed          Journal:  J Parasit Dis        ISSN: 0971-7196


  27 in total

1.  Molecular detection of Leishmania isolated from cutaneous leishmaniasis patients in Jask County, Hormozgan Province, Southern Iran, 2008.

Authors:  Koroush Azizi; Aboozar Soltani; Hamzeh Alipour
Journal:  Asian Pac J Trop Med       Date:  2012-07       Impact factor: 1.226

2.  Global burden of cutaneous leishmaniasis.

Authors:  Chante Karimkhani; Valentine Wanga; Paria Naghavi; Robert P Dellavalle; Mohsen Naghavi
Journal:  Lancet Infect Dis       Date:  2017-02-23       Impact factor: 25.071

3.  Glyburide, a NLRP3 Inhibitor, Decreases Inflammatory Response and Is a Candidate to Reduce Pathology in Leishmania braziliensis Infection.

Authors:  Augusto M Carvalho; Fernanda O Novais; Camilla S Paixão; Camila I de Oliveira; Paulo Roberto Lima Machado; Lucas P Carvalho; Phillip Scott; Edgar M Carvalho
Journal:  J Invest Dermatol       Date:  2019-06-25       Impact factor: 8.551

4.  Immune response in cutaneous leishmaniasis patients with healing vs. non-healing lesions.

Authors:  Akram Miramin-Mohammadi; Amir Javadi; Seyed Ebrahim Eskandari; Hossein Mortazavi; Mahmoud Nateghi Rostami; Ali Khamesipour
Journal:  Iran J Microbiol       Date:  2020-06

5.  Cutaneous leishmaniasis associated with Systemic Lupus Erythematosus (SLE).

Authors:  Qasem Asgari; Fatemeh Gholizadeh; Mohammad Nohtani; Mehdi Mirzaeipour; Mehdi Zare; Mohammad Saleh Bahreini
Journal:  Infez Med       Date:  2019-09-01

6.  Phagocytosis of hemozoin by RAW 264.7 cells, but not THP-1 cells, promotes infection by Leishmania donovani with a nitric oxide-independent mechanism.

Authors:  Erika van den Bogaart; Pètra F Mens; Emily R Adams; Martin P Grobusch; Henk D F H Schallig
Journal:  Parasitol Int       Date:  2016-09-10       Impact factor: 2.230

7.  Interleukin 17 production among patients with American cutaneous leishmaniasis.

Authors:  Olívia Bacellar; Daniela Faria; Márcia Nascimento; Thiago M Cardoso; Kenneth J Gollob; Walderez O Dutra; Phillip Scott; Edgar M Carvalho
Journal:  J Infect Dis       Date:  2009-07-01       Impact factor: 5.226

8.  Insufficient generation of Th17 cells in IL-23p19-deficient BALB/c mice protects against progressive cutaneous leishmaniasis.

Authors:  Kirsten Dietze-Schwonberg; Beate Lorenz; Susanna Lopez Kostka; Beatrix Schumak; André Gessner; Esther von Stebut
Journal:  Exp Dermatol       Date:  2017-12-06       Impact factor: 3.960

9.  A Comparative Evaluation of Regulatory T Cells Profile among Acute and Chronic Cutaneous Leishmaniasis Using Flow Cytometry.

Authors:  Fahimeh Firouzjaie-Karder; Behnaz Akhoundi; Mehdi Mohebali; Farid Azmoudeh Ardalan; Abbas Rahimi-Foroushani; Fatemeh Mesgarian; Homa Hajjaran; Hossein Mortazavi; Yadollah Shakiba; Sorour Charehdar; Samira Elikaee; Zahra Kakooei; Zahra Shafeghat
Journal:  Iran J Parasitol       Date:  2019 Apr-Jun       Impact factor: 1.012

10.  Potent antileishmanial activity of chitosan against Iranian strain of Leishmania major (MRHO/IR/75/ER): In vitro and in vivo assay.

Authors:  Bahman Rahimi Esboei; Mehdi Mohebali; Parisa Mousavi; Mahdi Fakhar; Behnaz Akhoundi
Journal:  J Vector Borne Dis       Date:  2018 Apr-Jun       Impact factor: 1.688

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.